Testing a new drug called SRN-101 before surgery for adults with high-grade glioma that has come back
Official title: A Study of SRN-101 Administered Prior to Surgical Resection in Adults With Recurrent High-Grade Glioma.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This study is testing a new drug, SRN-101, in adults whose high-grade glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary has come back and who can have surgery.
Read our full plain-language summary
What the trial team says
SRN-101 is designed to destroys tumor cells while simultaneously activating the immune system to fight cancer. This is a first in human, single arm study to evaluate SRN-101 for the treatment of adults with recurrent high-grade glioma (rHGG) who are eligible for resection.
Key facts
- Registry number
- NCT07826949
- Stage of testing
- Phase 1
- Conditions studied
- Recurrent High-Grade Gliomas, Brain Neoplasm, Glioma
Where it is running
This trial lists 1 site.
-
California
- University of California, San Francisco (San Francisco)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.